Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Iclusig

(i-KLOO-sig)
A drug used alone or with other drugs to treat adults with certain types of chronic myelogenous leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia. It is used in patients whose cancer is newly diagnosed, has the T315I mutation, or cannot be treated with other kinase inhibitors. It is also being studied in the treatment of other types of cancer. Iclusig blocks BCR::ABL1 and other proteins, which may help keep cancer cells from growing and may kill them. It may also prevent the growth of new blood vessels that tumors need to grow. Iclusig is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called ponatinib hydrochloride.
More Information
Search NCI's Dictionary of Cancer Terms